Rhythm Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company's lead product candidate, setmelanotide, is a melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity, including pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome, and Alström syndrome. Rhythm Pharmaceuticals was founded in 2008 and is headquartered in Carlsbad, California.